Modality
ASO
MOA
Menini
Target
PRMT5
Pathway
Hedgehog
HST2D
Development Pipeline
Preclinical
~Oct 2014
→ ~Jan 2016
Phase 1
~Apr 2016
→ ~Jul 2017
Phase 2
~Oct 2017
→ ~Jan 2019
Phase 3
~Apr 2019
→ ~Jul 2020
NDA/BLA
~Oct 2020
→ ~Jan 2022
Approved
Apr 2022
→ Jan 2029
ApprovedCurrent
NCT05149189
916 pts·HS
2024-11→2025-03·Active
NCT07431867
1,270 pts·HS
2024-10→2027-12·Terminated
NCT06469772
2,062 pts·HS
2022-04→2029-01·Recruiting
4,248 total pts1 indication
CompletedCurrentUpcoming
Catalysts (3)
2025-03-101.1y agoPh3 Readout· HS
2027-12-271.7y awayPh3 Readout· HS
2029-01-212.8y awayPh3 Readout· HS
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029
Approved
Recruit…
Approved
Termina…
Approved
Active
Catalysts
Ph3 Readout
2025-03-10 · 1.1y ago
HS
Ph3 Readout
2027-12-27 · 1.7y away
HS
Ph3 Readout
2029-01-21 · 2.8y away
HS
RecruitingActiveTerminated|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05149189 | Approved | HS | Active | 916 | BodyWt |
| NCT07431867 | Approved | HS | Terminated | 1270 | PFS |
| NCT06469772 | Approved | HS | Recruiting | 2062 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| Elrarapivir | Vertex Pharma | NDA/BLA | PRMT5 |